Interactions between gut microbiota and polyphenols: A mechanistic and metabolomic review

H Cheng, D Zhang, J Wu, J Liu, Y Zhou, Y Tan, W Feng… - Phytomedicine, 2023 - Elsevier
Background Polyphenols are a class of naturally sourced compounds with widespread
distribution and an extensive array of bioactivities. However, due to their complex …

The treatment of Cushing's disease

R Pivonello, M De Leo, A Cozzolino… - Endocrine …, 2015 - academic.oup.com
Abstract Cushing's disease (CD), or pituitary-dependent Cushing's syndrome, is a severe
endocrine disease caused by a corticotroph pituitary tumor and associated with increased …

Somatostatin receptors: from signaling to clinical practice

M Theodoropoulou, GK Stalla - Frontiers in neuroendocrinology, 2013 - Elsevier
Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Cushing's syndrome

J Newell-Price, X Bertagna, AB Grossman, LK Nieman - The Lancet, 2006 - thelancet.com
Cushing's syndrome results from lengthy and inappropriate exposure to excessive
glucocorticoids. Untreated, it has significant morbidity and mortality. The syndrome remains …

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

BMK Biller, AB Grossman, PM Stewart… - The Journal of …, 2008 - academic.oup.com
Objective: Our objective was to evaluate the published literature and reach a consensus on
the treatment of patients with ACTH-dependent Cushing's syndrome, because there is no …

MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects

RA Feelders, SJ Pulgar, A Kempel… - European journal of …, 2012 - academic.oup.com
Objective Cushing's disease (CD) is a rare endocrine disorder characterized by excess
secretion of ACTH due to a pituitary adenoma. Current treatment options are limited and …

Advances in the medical treatment of Cushing's syndrome

RA Feelders, J Newell-Price, R Pivonello… - The lancet Diabetes & …, 2019 - thelancet.com
Cushing's syndrome is associated with multisystem morbidity and, when suboptimally
treated, increased mortality. Medical therapy is an option for patients if surgery is not …

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

R Pivonello, MC De Martino… - The Journal of …, 2009 - academic.oup.com
Background: The role of dopamine agonists in the treatment of Cushing's disease (CD) has
been previously debated. Aim: The aim of this study was to evaluate the effectiveness of …

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial

M Boscaro, WH Ludlam, B Atkinson… - The Journal of …, 2009 - academic.oup.com
Context: There is currently no medical therapy for Cushing's disease that targets the pituitary
adenoma. Availability of such a medical therapy would be a valuable therapeutic option for …

Glucose metabolism abnormalities in Cushing syndrome: from molecular basis to clinical management

C Scaroni, M Zilio, M Foti, M Boscaro - Endocrine reviews, 2017 - academic.oup.com
An impaired glucose metabolism, which often leads to the onset of diabetes mellitus (DM), is
a common complication of chronic exposure to exogenous and endogenous glucocorticoid …